Lv3
230 积分 2024-02-18 加入
EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer
1小时前
待确认
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
6个月前
已完结
MA04.02 Nautika1: Clinical Outcomes and Pathologic Regression With Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK + NSCLC
6个月前
已关闭
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial
7个月前
已完结
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
9个月前
已完结
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
11个月前
已完结
皖公网安备34019202002308
